Tandem Diabetes Care, Inc. (TNDM)
- Previous Close
31.73 - Open
32.55 - Bid 34.94 x 200
- Ask 35.02 x 400
- Day's Range
32.51 - 35.01 - 52 Week Range
13.82 - 40.74 - Volume
2,348,319 - Avg. Volume
1,737,879 - Market Cap (intraday)
2.258B - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
-- - EPS (TTM)
-3.43 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
36.14
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
www.tandemdiabetes.comRecent News: TNDM
Performance Overview: TNDM
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TNDM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TNDM
Valuation Measures
Market Cap
2.26B
Enterprise Value
2.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.04
Price/Book (mrq)
7.20
Enterprise Value/Revenue
2.95
Enterprise Value/EBITDA
-11.19
Financial Highlights
Profitability and Income Statement
Profit Margin
-29.77%
Return on Assets (ttm)
-9.63%
Return on Equity (ttm)
-59.08%
Revenue (ttm)
747.72M
Net Income Avi to Common (ttm)
-222.61M
Diluted EPS (ttm)
-3.43
Balance Sheet and Cash Flow
Total Cash (mrq)
467.91M
Total Debt/Equity (mrq)
134.03%
Levered Free Cash Flow (ttm)
-69.3M
Research Analysis: TNDM
Company Insights: TNDM
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: TNDM
TNDM: Lowering target price to $30.00
TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetTNDM: Raising target price to $31.00
TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $31.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetTNDM: What does Argus have to say about TNDM?
TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetTNDM: Raising target price to $30.00
TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target